Navigation Links
Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
Date:12/9/2008

Data Support Case for DNA-Guided Medicine in Psychiatry

HARTFORD, Conn., Dec. 9 /PRNewswire/ -- Results from a clinical study published in the current issue of the Future Medicine Group (London) journal Personalized Medicine (Vol. 5, No. 6, pp. 579-587, 2008) are helping to point the way toward the application of DNA-guided medicine to predict psychotropic side effects. The study was conducted at The Institute of Living of Hartford Hospital in collaboration with Genomas.

The CYP2C9, CYP2C19 and CYP2D6 genes from the cytochrome P450 family were chosen for DNA typing because their common variants result in deficient metabolic capacity for many psychotropic drugs. Combinatorial gene analysis revealed that 57 percent of individuals in the psychiatric population were carriers of multiple gene variations associated with no or poor drug metabolism capacity on 2 or 3 genes compared to 36 percent of individuals in the control population. Individuals that are multiply deficient in CYP450 metabolic routes are at risk for developing serious side effects to a variety of psychotropic medications.

"We found clear evidence that there were significantly more innate drug metabolism deficiencies based on the gene variants predominantly observed in the population experiencing side effects," said Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, and Director of Genetics Research, Hartford Hospital. "Our goal is to enhance patient safety by preventing predictable side effects and at the same time build the case for DNA typing in the optimized utilization of health care resources. We are integrating this clinical experience with development of our PhyzioType Systems for DNA-Guided Medicine."

ABOUT GENOMAS

Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary Phyzio
'/>"/>

SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Rochester Medical Corpora...sults for its fourth quarter and year ended Septem...$9,009,000 for the current quarter compared to $9,...Company reported a quarterly net loss of $229,000 ... of $342,000 or $.03 per diluted share for the fou...
(Date:11/5/2009)...Newswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. ... for the third quarter ended September 30, 2009. ... were $30.8 million, compared to $17.7 million for... (sodium oxybate) oral solution net sales for the ... to $14.2 million for the third quarter of 2008, a...
(Date:11/5/2009)...ire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SM... the global orthopaedic device industry and other ...ncial results for the period ended October 3, 2009...r Vs Prior Quarter, share data) ... ----- ------ ------ ...
Breaking Medicine Technology:Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 7Symmetry Medical Reports Third Quarter 2009 Financial Results 2Symmetry Medical Reports Third Quarter 2009 Financial Results 3Symmetry Medical Reports Third Quarter 2009 Financial Results 4Symmetry Medical Reports Third Quarter 2009 Financial Results 5Symmetry Medical Reports Third Quarter 2009 Financial Results 6Symmetry Medical Reports Third Quarter 2009 Financial Results 7Symmetry Medical Reports Third Quarter 2009 Financial Results 8Sigma Aldrich 28Nasdaq 3A SIAL 29 Announces Appointment of George Miller as Sr Vice President General Counsel 26amp 3B Secretary 5174 1Sigma Aldrich 28Nasdaq 3A SIAL 29 Announces Appointment of George Miller as Sr Vice President General Counsel 26amp 3B Secretary 5174 2Pre Pregnancy Weight Linked to Babies Heart Problems 58714 1Pre Pregnancy Weight Linked to Babies Heart Problems 58714 2AARP Says No Way to No Social Security COLA in 2010 58709 1
...--(BUSINESS WIRE)--May 15, 2007 - Gemin X Biotechn...ed in the journal Blood,demonstrated that its lead...h in vitro in Mantle Cell Lymphoma (MCL) cell line...x (GX15-070) is a small,molecule specifically desi...protein family, a validated cancer target, thus re...
...howed Bioequivalence , LONDON, UK and ATLANTA, US,...YE) and Sciele Pharma. Inc. (NASDAQ:SCRX) today,an...rial programme,for the new formulation of Sular, a... of high blood pressure.,The study results showed ... Sciele,s currently marketed Sular. The new,Sular...
Other Medicine Technology:Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:11/5/2009)...TON, Nov. 5 Carriage Ser...fective November 4, 2009, it has amended and exten...dit facility with its lenders, Bank of America and...illion credit facility was scheduled to mature in ...amount of $40 million with an accordion provision ...
(Date:11/5/2009)...lready approved for the treatment of lymphoma may ...r in children and teens, according to an early-sta...nal Journal of Cancer . The study drug, Bortezomib... human cancer cell studies and in mice. While key ...osely resembled the human form and the drug has al...
(Date:11/5/2009)...rman newborns show crying patterns that mimic pare... Nov. 5 (HealthDay News) -- Infants who are just a...flect the language spoken by their parents, new re...researchers is that fetuses are listening closely ...nancy, laying the groundwork for learning language...
(Date:11/5/2009)... and national campaign finance watchdogs ask: Who ... Iowa Sen. Chuck Grassle... the 3rd quarter of 2009 from health care interest...ts, according to research conducted by the campaig...assley serves as the ranking Republican on the Sen...
(Date:11/5/2009)...FIELD, Calif., Nov. 5 ChemSW is pl...dorRate Report. The only Internet site that offer...arisons of technology vendors, VendorRate has list... Q3 2009 Customer Satisfaction Industry Report. ,...stomer satisfaction score was the lowest ever repo...
Breaking Medicine News(10 mins):Health News:Carriage Services Amends and Extends Credit Facility 2Health News:Approved lymphoma drug shows promise in early tests against bone cancer 2Health News:Fetus Learns Intonations of Mother's Tongue 2Health News:Fetus Learns Intonations of Mother's Tongue 3Health News:Sen. Grassley Raised More Than $150,000 Over the Summer From Health Care and Insurance Interests 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2
...posal that pregnant South African schoolgirls be a... in the country amid fears// that this could encou... pressure to deal with the high number of teenager...llows pregnant girls to return to school after the...
... Louis, researcher and member of Washington Univer...ks best in fighting the risk factors // for diabet...s Louis, who is currently involved in new research...tes. "Both diet and exercise provide profound ...
...nternet which is a reservoir of information has do...// In a society that is largely technology driven,...ith information available with a mere tap of the f...to health. While acknowledging that it is imp...
...ian Health department and medical regulatory offic... drug for the treatment of arthritis// called Prex...eems to have no other side effects like cardiac co... class, such as Vioxx and Bextra have reported hea...
...sies and thoughts of erotic pictures and sensuous...n and holds him in rapt attention// and causes a m... the recesses of his mind says scientists who con...d image of female nude or sexually arousing pictur...
...ive parenting habits may be the reason for enhance...ved superiority of breast milk// over bottle milk ... hold water, a new study has shown. The findings ...reast milk, was beneficial in the improvement of v...
Other Medicine News:Health News:Maternity leave mooted for South African girls 2Health News:Lose Weight To Reduce Risk Of Diabetes – Says A New Researc 2Health News:If The World Wide Web is Your Self Proclaimed Physician, Trouble Could be Just a Click Away 2Health News:Naked truths and Basic Instincts 2Health News:Children’s Verbal Skills Are Sharpened by Positive Parenting Behavior 2
... you with an alternative method for monitoring epi...gn as Ad-Techs Spencer Probe Depth Electrodes, exc...le instead of a stylet. Features include a smaller...g contacts, 5.0 mm standard contact spacing, and d...
...or controlled tissue modification in small joint a...lleable tip, controlled capsuloligamentous or tend...hieved. When used in conjunction with the OPES Ele...real time tissue impedance tracking allows the,O...
Swanson Titanium Carpal Scaphoid Implant
...l-4V) screw offered in two diameters (Standard and...e loaded together as one screw and sterile package...ssary for implantation or removal of both Standard...ssor is a unique design where the screw achieves m...
Medicine Products: